Results: Keyword

LIST OF BINDING INTERFACES for query 'PROTEASOME SUBUNIT BETA' in category 'PROTEIN NAME'

(Click on the 'Details' column to view details on interfaces and similar patterns of amino acids)
Click on the 'View' column to view patterns on the structural viewer)

PDB	Ligand	Drug	Indication	Macromolecule/ Organism	Pfam	Binding_Interfaces (View)	Details
4qvp	BO2	Bortezomib (DB00188)	Bortezomib is a proteasome inhibitor used to treat multiple myeloma in patients who have not been successfully treated with at least two previous therapies.	PROTEASOME SUBUNIT BETA TYPE-2; PROTEASOME SUBUNIT BETA TYPE-3 (Saccharomyces cerevisiae)	Pr_beta_C Proteasome	4QVP_H_BO2H301 4QVP_K_BO2K301 4QVP_N_BO2N201
4qvp	BO2	Bortezomib (DB00188)	Bortezomib is a proteasome inhibitor used to treat multiple myeloma in patients who have not been successfully treated with at least two previous therapies.	PROTEASOME SUBUNIT BETA TYPE-5; PROTEASOME SUBUNIT BETA TYPE-6 (Saccharomyces cerevisiae)	Proteasome	4QVP_H_BO2H301 4QVP_K_BO2K301 4QVP_N_BO2N201
4qvp	BO2	Bortezomib (DB00188)	Bortezomib is a proteasome inhibitor used to treat multiple myeloma in patients who have not been successfully treated with at least two previous therapies.	PROTEASOME SUBUNIT BETA TYPE-1; PROTEASOME SUBUNIT BETA TYPE-2 (Saccharomyces cerevisiae)	Pr_beta_C	4QVP_H_BO2H301 4QVP_K_BO2K301 4QVP_N_BO2N201
4r67	3BV	Carfilzomib (DB08889)	Carfilzomib is a proteasome inhibitor used either alone or in conjunction with a chemotherapy regimen to treat patients with relapsed or refractory multiple myeloma.	PROTEASOME SUBUNIT BETA TYPE-6; PROTEASOME SUBUNIT BETA TYPE-7 (Homo sapiens)	NA	4R67_H_3BVH301 4R67_I_3BVI301 4R67_L_3BVL301
4r67	3BV	Carfilzomib (DB08889)	Carfilzomib is a proteasome inhibitor used either alone or in conjunction with a chemotherapy regimen to treat patients with relapsed or refractory multiple myeloma.	PROTEASOME SUBUNIT BETA TYPE-3; PROTEASOME SUBUNIT BETA TYPE-7 (Homo sapiens)	Proteasome	4R67_H_3BVH301 4R67_I_3BVI301 4R67_L_3BVL301
4r67	3BV	Carfilzomib (DB08889)	Carfilzomib is a proteasome inhibitor used either alone or in conjunction with a chemotherapy regimen to treat patients with relapsed or refractory multiple myeloma.	PROTEASOME SUBUNIT BETA TYPE-1; PROTEASOME SUBUNIT BETA TYPE-5 (Homo sapiens)	Proteasome	4R67_H_3BVH301 4R67_I_3BVI301 4R67_L_3BVL301
5d0s	3BV	Carfilzomib (DB08889)	Carfilzomib is a proteasome inhibitor used either alone or in conjunction with a chemotherapy regimen to treat patients with relapsed or refractory multiple myeloma.	PROTEASOME SUBUNIT BETA TYPE-2; PROTEASOME SUBUNIT BETA TYPE-3 (Saccharomyces cerevisiae (strain atcc 204508 / s288c))	Pr_beta_C Proteasome	5D0S_H_3BVH301 5D0S_K_3BVK301 5D0S_N_3BVN201
5d0s	3BV	Carfilzomib (DB08889)	Carfilzomib is a proteasome inhibitor used either alone or in conjunction with a chemotherapy regimen to treat patients with relapsed or refractory multiple myeloma.	PROTEASOME SUBUNIT BETA TYPE-5; PROTEASOME SUBUNIT BETA TYPE-6 (Saccharomyces cerevisiae (strain atcc 204508 / s288c))	Proteasome	5D0S_H_3BVH301 5D0S_K_3BVK301 5D0S_N_3BVN201
5d0s	3BV	Carfilzomib (DB08889)	Carfilzomib is a proteasome inhibitor used either alone or in conjunction with a chemotherapy regimen to treat patients with relapsed or refractory multiple myeloma.	PROTEASOME SUBUNIT BETA TYPE-1; PROTEASOME SUBUNIT BETA TYPE-2 (Saccharomyces cerevisiae (strain atcc 204508 / s288c))	Pr_beta_C	5D0S_H_3BVH301 5D0S_K_3BVK301 5D0S_N_3BVN201
5l5e	3BV	Carfilzomib (DB08889)	Carfilzomib is a proteasome inhibitor used either alone or in conjunction with a chemotherapy regimen to treat patients with relapsed or refractory multiple myeloma.	PROTEASOME SUBUNIT BETA TYPE-6,PROTEASOME SUBUNIT BETA TYPE-1,PROTEASOME SUBUNIT BETA TYPE-6,PROTEASOME SUBUNIT BETA TYPE-1,PROTEASOME SUBUNIT BETA TYPE-6; PROTEASOME SUBUNIT BETA TYPE-8,PROTEASOME SUBUNIT BETA TYPE-5 (Saccharomyces cerevisiae (strain atcc 204508 / s288c); homo sapiens; saccharomyces cerevisiae)	Proteasome	5L5E_K_3BVK301
5l5f	BO2	Bortezomib (DB00188)	Bortezomib is a proteasome inhibitor used to treat multiple myeloma in patients who have not been successfully treated with at least two previous therapies.	PROTEASOME SUBUNIT BETA TYPE-6,PROTEASOME SUBUNIT BETA TYPE-1,PROTEASOME SUBUNIT BETA TYPE-6,PROTEASOME SUBUNIT BETA TYPE-1,PROTEASOME SUBUNIT BETA TYPE-6; PROTEASOME SUBUNIT BETA TYPE-8,PROTEASOME SUBUNIT BETA TYPE-5 (Saccharomyces cerevisiae (strain atcc 204508 / s288c); homo sapiens; saccharomyces cerevisiae)	Proteasome	5L5F_K_BO2K301
5l5y	3BV	Carfilzomib (DB08889)	Carfilzomib is a proteasome inhibitor used either alone or in conjunction with a chemotherapy regimen to treat patients with relapsed or refractory multiple myeloma.	PROTEASOME SUBUNIT BETA TYPE-5,PROTEASOME SUBUNIT BETA TYPE-5; PROTEASOME SUBUNIT BETA TYPE-6,PROTEASOME SUBUNIT BETA TYPE-1,PROTEASOME SUBUNIT BETA TYPE-6,PROTEASOME SUBUNIT BETA TYPE-1,PROTEASOME SUBUNIT BETA TYPE-6 (Homo sapiens; saccharomyces cerevisiae (strain atcc 204508 / s288c); saccharomyces cerevisiae)	Proteasome	5L5Y_K_3BVK301
5l5z	BO2	Bortezomib (DB00188)	Bortezomib is a proteasome inhibitor used to treat multiple myeloma in patients who have not been successfully treated with at least two previous therapies.	PROTEASOME SUBUNIT BETA TYPE-5,PROTEASOME SUBUNIT BETA TYPE-5; PROTEASOME SUBUNIT BETA TYPE-6,PROTEASOME SUBUNIT BETA TYPE-1,PROTEASOME SUBUNIT BETA TYPE-6,PROTEASOME SUBUNIT BETA TYPE-1,PROTEASOME SUBUNIT BETA TYPE-6 (Homo sapiens; saccharomyces cerevisiae (strain atcc 204508 / s288c); saccharomyces cerevisiae)	Proteasome	5L5Z_K_BO2K301
5lf3	BO2	Bortezomib (DB00188)	Bortezomib is a proteasome inhibitor used to treat multiple myeloma in patients who have not been successfully treated with at least two previous therapies.	PROTEASOME SUBUNIT BETA TYPE-3; PROTEASOME SUBUNIT BETA TYPE-7 (Homo sapiens)	Pr_beta_C Proteasome	5LF3_H_BO2H306 5LF3_K_BO2K305 5LF3_N_BO2N304
5lf3	BO2	Bortezomib (DB00188)	Bortezomib is a proteasome inhibitor used to treat multiple myeloma in patients who have not been successfully treated with at least two previous therapies.	PROTEASOME SUBUNIT BETA TYPE-1; PROTEASOME SUBUNIT BETA TYPE-5 (Homo sapiens)	Proteasome	5LF3_H_BO2H306 5LF3_K_BO2K305 5LF3_N_BO2N304
5lf3	BO2	Bortezomib (DB00188)	Bortezomib is a proteasome inhibitor used to treat multiple myeloma in patients who have not been successfully treated with at least two previous therapies.	PROTEASOME SUBUNIT BETA TYPE-6; PROTEASOME SUBUNIT BETA TYPE-7 (Homo sapiens)	Pr_beta_C	5LF3_H_BO2H306 5LF3_K_BO2K305 5LF3_N_BO2N304
5lf7	6V8	Ixazomib (DB09570)	Ixazomib is a monoclonal antibody used with other medications to treat multiple myeloma in patients who have received one other therapy already.	PROTEASOME SUBUNIT BETA TYPE-3; PROTEASOME SUBUNIT BETA TYPE-7 (Homo sapiens)	Pr_beta_C Proteasome	5LF7_H_6V8H305 5LF7_K_6V8K305 5LF7_N_6V8N305
5lf7	6V8	Ixazomib (DB09570)	Ixazomib is a monoclonal antibody used with other medications to treat multiple myeloma in patients who have received one other therapy already.	PROTEASOME SUBUNIT BETA TYPE-1; PROTEASOME SUBUNIT BETA TYPE-5 (Homo sapiens)	Proteasome	5LF7_H_6V8H305 5LF7_K_6V8K305 5LF7_N_6V8N305
5lf7	6V8	Ixazomib (DB09570)	Ixazomib is a monoclonal antibody used with other medications to treat multiple myeloma in patients who have received one other therapy already.	PROTEASOME SUBUNIT BETA TYPE-6; PROTEASOME SUBUNIT BETA TYPE-7 (Homo sapiens)	Pr_beta_C	5LF7_H_6V8H305 5LF7_K_6V8K305 5LF7_N_6V8N305
6td5	BO2	Bortezomib (DB00188)	Bortezomib is a proteasome inhibitor used to treat multiple myeloma in patients who have not been successfully treated with at least two previous therapies.	PROTEASOME SUBUNIT BETA (Leishmania donovani)	NA	6TD5_H_BO2H301 6TD5_I_BO2I301 6TD5_L_BO2L401
6td5	BO2	Bortezomib (DB00188)	Bortezomib is a proteasome inhibitor used to treat multiple myeloma in patients who have not been successfully treated with at least two previous therapies.	PROTEASOME SUBUNIT BETA (Leishmania donovani)	Proteasome	6TD5_H_BO2H301 6TD5_I_BO2I301 6TD5_L_BO2L401
PDB	Ligand	Drug	Indication	Macromolecule/ Organism	Pfam	Binding_Interfaces (View)	Details

[["4qvp","BO2","Bortezomib (DB00188)","Saccharomyces cerevisiae","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","Pr_beta_C;Proteasome"],["4qvp","BO2","Bortezomib (DB00188)","Saccharomyces cerevisiae","PROTEASOME SUBUNIT BETA TYPE-5;PROTEASOME SUBUNIT BETA TYPE-6","Proteasome"],["4qvp","BO2","Bortezomib (DB00188)","Saccharomyces cerevisiae","PROTEASOME SUBUNIT BETA TYPE-1;PROTEASOME SUBUNIT BETA TYPE-2","Pr_beta_C"],["4r67","3BV","Carfilzomib (DB08889)","Homo sapiens","PROTEASOME SUBUNIT BETA TYPE-6;PROTEASOME SUBUNIT BETA TYPE-7","NA"],["4r67","3BV","Carfilzomib (DB08889)","Homo sapiens","PROTEASOME SUBUNIT BETA TYPE-3;PROTEASOME SUBUNIT BETA TYPE-7","Proteasome"],["4r67","3BV","Carfilzomib (DB08889)","Homo sapiens","PROTEASOME SUBUNIT BETA TYPE-1;PROTEASOME SUBUNIT BETA TYPE-5","Proteasome"],["5d0s","3BV","Carfilzomib (DB08889)","Saccharomyces cerevisiae (strain atcc 204508 \/ s288c)","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","Pr_beta_C;Proteasome"],["5d0s","3BV","Carfilzomib (DB08889)","Saccharomyces cerevisiae (strain atcc 204508 \/ s288c)","PROTEASOME SUBUNIT BETA TYPE-5;PROTEASOME SUBUNIT BETA TYPE-6","Proteasome"],["5d0s","3BV","Carfilzomib (DB08889)","Saccharomyces cerevisiae (strain atcc 204508 \/ s288c)","PROTEASOME SUBUNIT BETA TYPE-1;PROTEASOME SUBUNIT BETA TYPE-2","Pr_beta_C"],["5l5e","3BV","Carfilzomib (DB08889)","Saccharomyces cerevisiae (strain atcc 204508 \/ s288c);homo sapiens;saccharomyces cerevisiae","PROTEASOME SUBUNIT BETA TYPE-6,PROTEASOME SUBUNIT BETA TYPE-1,PROTEASOME SUBUNIT BETA TYPE-6,PROTEASOME SUBUNIT BETA TYPE-1,PROTEASOME SUBUNIT BETA TYPE-6;PROTEASOME SUBUNIT BETA TYPE-8,PROTEASOME SUBUNIT BETA TYPE-5","Proteasome"],["5l5f","BO2","Bortezomib (DB00188)","Saccharomyces cerevisiae (strain atcc 204508 \/ s288c);homo sapiens;saccharomyces cerevisiae","PROTEASOME SUBUNIT BETA TYPE-6,PROTEASOME SUBUNIT BETA TYPE-1,PROTEASOME SUBUNIT BETA TYPE-6,PROTEASOME SUBUNIT BETA TYPE-1,PROTEASOME SUBUNIT BETA TYPE-6;PROTEASOME SUBUNIT BETA TYPE-8,PROTEASOME SUBUNIT BETA TYPE-5","Proteasome"],["5l5y","3BV","Carfilzomib (DB08889)","Homo sapiens;saccharomyces cerevisiae (strain atcc 204508 \/ s288c);saccharomyces cerevisiae","PROTEASOME SUBUNIT BETA TYPE-5,PROTEASOME SUBUNIT BETA TYPE-5;PROTEASOME SUBUNIT BETA TYPE-6,PROTEASOME SUBUNIT BETA TYPE-1,PROTEASOME SUBUNIT BETA TYPE-6,PROTEASOME SUBUNIT BETA TYPE-1,PROTEASOME SUBUNIT BETA TYPE-6","Proteasome"],["5l5z","BO2","Bortezomib (DB00188)","Homo sapiens;saccharomyces cerevisiae (strain atcc 204508 \/ s288c);saccharomyces cerevisiae","PROTEASOME SUBUNIT BETA TYPE-5,PROTEASOME SUBUNIT BETA TYPE-5;PROTEASOME SUBUNIT BETA TYPE-6,PROTEASOME SUBUNIT BETA TYPE-1,PROTEASOME SUBUNIT BETA TYPE-6,PROTEASOME SUBUNIT BETA TYPE-1,PROTEASOME SUBUNIT BETA TYPE-6","Proteasome"],["5lf3","BO2","Bortezomib (DB00188)","Homo sapiens","PROTEASOME SUBUNIT BETA TYPE-3;PROTEASOME SUBUNIT BETA TYPE-7","Pr_beta_C;Proteasome"],["5lf3","BO2","Bortezomib (DB00188)","Homo sapiens","PROTEASOME SUBUNIT BETA TYPE-1;PROTEASOME SUBUNIT BETA TYPE-5","Proteasome"],["5lf3","BO2","Bortezomib (DB00188)","Homo sapiens","PROTEASOME SUBUNIT BETA TYPE-6;PROTEASOME SUBUNIT BETA TYPE-7","Pr_beta_C"],["5lf7","6V8","Ixazomib (DB09570)","Homo sapiens","PROTEASOME SUBUNIT BETA TYPE-3;PROTEASOME SUBUNIT BETA TYPE-7","Pr_beta_C;Proteasome"],["5lf7","6V8","Ixazomib (DB09570)","Homo sapiens","PROTEASOME SUBUNIT BETA TYPE-1;PROTEASOME SUBUNIT BETA TYPE-5","Proteasome"],["5lf7","6V8","Ixazomib (DB09570)","Homo sapiens","PROTEASOME SUBUNIT BETA TYPE-6;PROTEASOME SUBUNIT BETA TYPE-7","Pr_beta_C"],["6td5","BO2","Bortezomib (DB00188)","Leishmania donovani","PROTEASOME SUBUNIT BETA","NA"],["6td5","BO2","Bortezomib (DB00188)","Leishmania donovani","PROTEASOME SUBUNIT BETA","Proteasome"]]